> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Panel Meets to Review Victoza sNDA
- URL: https://www.fdaweb.com/fda-panel-meets-to-review-victoza-snda/
- Published: 2017-05-23T12:00:00.000Z
- Updated: 2026-09-14T22:25:06.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138768

*Federal Register* notice: FDA has announced a 6/20 Endocrinologic and Metabolic Drugs Advisory Committee meeting. The panel is scheduled to discuss a supplemental NDA for Novo Nordisk’s Victoza (liraglutide) injection for a proposed additional indication as an adjunct to standard treatment of cardiovascular risk factors to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with Type 2 diabetes mellitus and high cardiovascular risk. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-05-22/pdf/2017-10326.pdf?ref=fdaweb.com).